BioArctic and Novartis Form Strategic Alliance for BrainTransporter™ Technology
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has announced a significant collaboration with Novartis Pharma AG, focusing on the integration of its proprietary BrainTransporter technology in addressing neurodegenerative diseases. This strategic alliance marks a notable milestone in BioArctic's commitment to pioneering innovative approaches in biopharma.
Collaboration Overview and Financials
The agreement involves an upfront payment of USD 30 million to BioArctic as part of the collaboration's initiation. Novartis aims to leverage this innovative technology in its research endeavors, evaluating the potential benefits of the BrainTransporter in developing new treatments for neurological disorders.
If Novartis opts to pursue additional development of any resulting drug candidates, BioArctic stands to gain further payments that could total up to USD 772 million. Moreover, BioArctic would benefit from tiered mid-single digit royalties on future product sales if the drug candidates successfully reach the market.
Research and Development Focus
As part of this collaboration, BioArctic will combine its BrainTransporter technology with a proprietary antibody from Novartis to create promising new drug candidates. The partnership is structured such that should Novartis decide to proceed with the development, they will assume all responsibilities for the global commercialization of the resulting products.
Gunilla Osswald, CEO at BioArctic, expressed her enthusiasm regarding the deal, stating, "The commitment from Novartis underscores our shared dedication to advancing science for patients with severe neurological disorders. Our BrainTransporter platform continues to demonstrate its versatility and potential for contributing to various innovative projects that can ultimately enhance patient outcomes."
Novartis' Commitment to Advancing Neurological Treatments
Sophie Parmentier Batteur, Head of Neurodegeneration Research at Novartis, underscored the significance of the partnership. She noted, "This collaboration allows us to harness the exciting potential of the BrainTransporter technology to ensure effective delivery of novel therapeutic agents to the brain. Our goal is to develop therapies that meaningfully impact disease progression, providing hope to patients grappling with severe neurological conditions."
BioArctic's Growth and Future Plans
This agreement is the third partnership that BioArctic has established involving the BrainTransporter technology. The company maintains all rights to the BrainTransporter outside of the collaborative frameworks currently in place, thereby positioning itself optimally for future opportunities across a spectrum of therapeutic areas.
BioArctic's BrainTransporter technology is designed to facilitate the delivery of biologics, such as antibodies, across the blood-brain barrier. This approach allows for wider distribution in the brain, potentially enhancing the efficacy of treatments while improving their safety profile and dosing convenience.
About BioArctic AB and Its Vision
BioArctic AB is dedicated to creating groundbreaking therapies that can arrest or slow down the progress of neurodegenerative conditions. Among their notable achievements is the development of Leqembi (lecanemab), the first drug shown to slow Alzheimer's disease progression while reducing cognitive impairment in early-stage patients. The company partners with Eisai for the global commercialization of Leqembi while simultaneously exploring additional treatments for conditions like Parkinson's disease and ALS.
With a robust research portfolio, BioArctic continues to innovate in drug development, including projects leveraging its proprietary BrainTransporter technology, which aims to enhance treatment efficacy by enabling effective delivery across the challenging blood-brain barrier.
Frequently Asked Questions
What is the focus of the collaboration between BioArctic and Novartis?
The collaboration aims to develop new treatments for neurodegenerative diseases using BioArctic’s BrainTransporter technology integrated with Novartis’ proprietary antibodies.
How much is BioArctic receiving upfront from Novartis?
BioArctic will receive an upfront payment of USD 30 million as part of the collaboration agreement.
What are the potential financial benefits for BioArctic?
If Novartis elects to proceed with drug candidates developed through this partnership, BioArctic could receive additional payments totaling up to USD 772 million, plus tiered royalties on future sales.
What is BrainTransporter technology?
BrainTransporter technology facilitates the passage of biological drugs across the blood-brain barrier, potentially improving treatment efficacy and safety profiles for neurological therapies.
What is BioArctic's mission?
BioArctic is focused on innovative solutions to delay or halt the progression of neurodegenerative diseases, enhancing patient treatment outcomes and quality of life.
